Tixagevimab/cilgavimab (Evusheld®).HTA ID: 22074

Assessment Status Rapid Review Complete
HTA ID 22074
Drug Tixagevimab/cilgavimab
Brand Evusheld®
Indication Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
Assessment Process
Rapid review commissioned 12/12/2022
Rapid review completed 25/01/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.